Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 3/20 | 0.32 |
| ▸ | LTA4H | P09960 | 3/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23451360 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTFAAHSMN1; SMN2KDM4E | |
| SCHEMBL21614000 | 0.99 | ALDH1A1 (0.35) | ALDH1A1MAPTFAAHSMN1; SMN2KDM4E | |
| SCHEMBL24837480 | 0.91 | FAAH (0.39) | ALDH1A1MAPTFAAHSMN1; SMN2KDM4E | |
| SCHEMBL23071873 | 0.89 | CASP1 (0.35) | ALDH1A1MAPTMMEACECPA1 | |
| SCHEMBL20529430 | 0.84 | HRH3 (0.33) | MAPT | |
| SCHEMBL20677186 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MAPTFAAHSMN1; SMN2KDM4E | |
| SCHEMBL19401861 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MAPTFAAHSMN1; SMN2KDM4E | |
| SCHEMBL20677185 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MAPTFAAHSMN1; SMN2KDM4E | |
| SCHEMBL31240223 | 0.81 | GLP1R (0.32) | — | |
| SCHEMBL20529554 | 0.80 | ALDH1A1 (0.38) | ALDH1A1MAPTFAAHSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20210393790-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
| EP-3818062-A1 | CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | Hangzhou Dac Biotech Co., Ltd (CN) | 2021-05-12 | — | — | EP | disclosed |
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
| EP-3606922-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | Hangzhou Dac Biotech Co., Ltd (CN) | 2020-02-12 | — | — | EP | disclosed |
| WO-2020006722-A1 | CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-01-09 | — | — | WO | disclosed |
| WO-2018185526-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | ALDH1A1 1130/4885MAPT 1665/4885FAAH 3316/4885 |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | ALDH1A1 1130/4885MAPT 1665/4885FAAH 3316/4885 |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | ALDH1A1 1130/4885MAPT 1665/4885FAAH 3316/4885 |
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | PBDC1, BRD2, CD79B | ALDH1A1 2260/4885MAPT 2303/4885FAAH 2127/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | ALDH1A1 60/4885MAPT 2442/4885FAAH 1871/4885 |
| US-20210393790-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | ALDH1A1 1130/4885MAPT 1665/4885FAAH 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.